Safety of nifedipine in subjects with bronchial asthma and COPD

N. Nair, R. G. Townley, Againdra K. Bewtra, C. K. Nair

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This prospective study was undertaken to evaluate the safety of nifedipine, a calcium channel blocking agent, on 60 subjects with asthma, chronic obstructive pulmonary disease (COPD), angina, and normal subjects. All subjects received nifedipine, 20 mg, sublingually. Spirometry was done pre-drug administration and every 20 minutes after for two hours. Parameters measured were forced vital capacity (FVC), forced expiratory volume in one second (FEV 1), and forced expiratory flow at 25 percent to 75 percent of total volume (FEF25-75%). Subjects with asthma and COPD were also given nifedipine 20 mg three times daily, orally for two weeks, and tested biweekly during this period. All bronchodilators, beta-blockers, and long acting nitrates were withheld for five half-lives of the drug prior to test day. There was no adverse effect on the pulmonary function. We found a statistically significant improvement (p1 after nifedipine. There was no tachyphlaxis at the end of two weeks. Nifedipine is safe in patients with asthma and/or chronic bronchitis.

Original languageEnglish
Pages (from-to)515-518
Number of pages4
JournalChest
Volume86
Issue number4
StatePublished - 1984

Fingerprint

Nifedipine
Chronic Obstructive Pulmonary Disease
Asthma
Safety
Bronchodilator Agents
Spirometry
Chronic Bronchitis
Vital Capacity
Forced Expiratory Volume
Calcium Channels
Pharmaceutical Preparations
Nitrates
Prospective Studies
Lung

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Nair, N., Townley, R. G., Bewtra, A. K., & Nair, C. K. (1984). Safety of nifedipine in subjects with bronchial asthma and COPD. Chest, 86(4), 515-518.

Safety of nifedipine in subjects with bronchial asthma and COPD. / Nair, N.; Townley, R. G.; Bewtra, Againdra K.; Nair, C. K.

In: Chest, Vol. 86, No. 4, 1984, p. 515-518.

Research output: Contribution to journalArticle

Nair, N, Townley, RG, Bewtra, AK & Nair, CK 1984, 'Safety of nifedipine in subjects with bronchial asthma and COPD', Chest, vol. 86, no. 4, pp. 515-518.
Nair, N. ; Townley, R. G. ; Bewtra, Againdra K. ; Nair, C. K. / Safety of nifedipine in subjects with bronchial asthma and COPD. In: Chest. 1984 ; Vol. 86, No. 4. pp. 515-518.
@article{789cfa0943984c0c893c97bc78de5e49,
title = "Safety of nifedipine in subjects with bronchial asthma and COPD",
abstract = "This prospective study was undertaken to evaluate the safety of nifedipine, a calcium channel blocking agent, on 60 subjects with asthma, chronic obstructive pulmonary disease (COPD), angina, and normal subjects. All subjects received nifedipine, 20 mg, sublingually. Spirometry was done pre-drug administration and every 20 minutes after for two hours. Parameters measured were forced vital capacity (FVC), forced expiratory volume in one second (FEV 1), and forced expiratory flow at 25 percent to 75 percent of total volume (FEF25-75{\%}). Subjects with asthma and COPD were also given nifedipine 20 mg three times daily, orally for two weeks, and tested biweekly during this period. All bronchodilators, beta-blockers, and long acting nitrates were withheld for five half-lives of the drug prior to test day. There was no adverse effect on the pulmonary function. We found a statistically significant improvement (p1 after nifedipine. There was no tachyphlaxis at the end of two weeks. Nifedipine is safe in patients with asthma and/or chronic bronchitis.",
author = "N. Nair and Townley, {R. G.} and Bewtra, {Againdra K.} and Nair, {C. K.}",
year = "1984",
language = "English",
volume = "86",
pages = "515--518",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - Safety of nifedipine in subjects with bronchial asthma and COPD

AU - Nair, N.

AU - Townley, R. G.

AU - Bewtra, Againdra K.

AU - Nair, C. K.

PY - 1984

Y1 - 1984

N2 - This prospective study was undertaken to evaluate the safety of nifedipine, a calcium channel blocking agent, on 60 subjects with asthma, chronic obstructive pulmonary disease (COPD), angina, and normal subjects. All subjects received nifedipine, 20 mg, sublingually. Spirometry was done pre-drug administration and every 20 minutes after for two hours. Parameters measured were forced vital capacity (FVC), forced expiratory volume in one second (FEV 1), and forced expiratory flow at 25 percent to 75 percent of total volume (FEF25-75%). Subjects with asthma and COPD were also given nifedipine 20 mg three times daily, orally for two weeks, and tested biweekly during this period. All bronchodilators, beta-blockers, and long acting nitrates were withheld for five half-lives of the drug prior to test day. There was no adverse effect on the pulmonary function. We found a statistically significant improvement (p1 after nifedipine. There was no tachyphlaxis at the end of two weeks. Nifedipine is safe in patients with asthma and/or chronic bronchitis.

AB - This prospective study was undertaken to evaluate the safety of nifedipine, a calcium channel blocking agent, on 60 subjects with asthma, chronic obstructive pulmonary disease (COPD), angina, and normal subjects. All subjects received nifedipine, 20 mg, sublingually. Spirometry was done pre-drug administration and every 20 minutes after for two hours. Parameters measured were forced vital capacity (FVC), forced expiratory volume in one second (FEV 1), and forced expiratory flow at 25 percent to 75 percent of total volume (FEF25-75%). Subjects with asthma and COPD were also given nifedipine 20 mg three times daily, orally for two weeks, and tested biweekly during this period. All bronchodilators, beta-blockers, and long acting nitrates were withheld for five half-lives of the drug prior to test day. There was no adverse effect on the pulmonary function. We found a statistically significant improvement (p1 after nifedipine. There was no tachyphlaxis at the end of two weeks. Nifedipine is safe in patients with asthma and/or chronic bronchitis.

UR - http://www.scopus.com/inward/record.url?scp=0021748608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021748608&partnerID=8YFLogxK

M3 - Article

C2 - 6478889

AN - SCOPUS:0021748608

VL - 86

SP - 515

EP - 518

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -